Investigational product

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

According to §3 of the GCP regulation, a clinical investigational product is a dosage form of an active substance or placebo that is tested in a clinical trial on humans or used as a comparator preparation or used to produce certain reactions in humans.

General informationThis section has been translated automatically.

Investigational medicinal products may either not be authorised or may already be available in another pharmaceutical form (e.g. drops instead of tablets). They may already be approved for other indications or may be used to compare new substances. The use of investigational medicinal products is defined in Directive 2001/20/EC, Commission Directive 2005/28/EC, the 12th Amendment to the German Medicines Act (AMG), and the GCP Regulation. All laws and guidelines serve especially to protect the study participants.

Before the substances may be used, an application for approval of the clinical trial must be submitted in accordance with § 40 - 42 AMG and § 7 of the GCP regulation. A manufacturing authorization from the pharmaceutical company in accordance with § 13 AMG must also be available and the investigational product must be labeled in accordance with § 5 of the GCP regulation. According to GCP § 4, the sponsor must ensure that the manufacture and testing of the preparation to be tested is carried out in accordance with the specifications of the submittedInvestigator Medicinal Product Dossier ( IMPD). The manufacture of investigational medicinal products must be carried out in accordance with "Good Manufacturing Practice". The manufacturing sites and testing laboratories must be suitable for testing and comply with the required standards. In addition to manufacturing regulations, there are also numerous provisions on shipping and quality requirements for substances to be tested in studies.

Investigational medicinal products must be labelled externally and contain the following information:

  • Contact details of the sponsor - the main responsible person must be identifiable
  • Protocol number and EudraCTnumber
  • name of the investigational medicinal product with batch number and encryption, if applicable
  • Shelf life and storage instructions (e.g. refrigerator)
  • Quantity and details of the application (e.g. i.v.- or peranal)
  • Dosage details
  • Assignment code to the study participant
  • Precautions (e.g. advice that the product should be stored out of the reach of children)

Authors

Last updated on: 29.10.2020